Equities analysts predict that Vascular Biogenics Ltd (NASDAQ:VBLT) will announce $240,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Vascular Biogenics’ earnings. The lowest sales estimate is $200,000.00 and the highest is $280,000.00. Vascular Biogenics posted sales of $100,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 140%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 19th.

According to Zacks, analysts expect that Vascular Biogenics will report full year sales of $810,000.00 for the current year, with estimates ranging from $700,000.00 to $920,000.00. For the next financial year, analysts anticipate that the company will post sales of $870,000.00, with estimates ranging from $600,000.00 to $1.13 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.25 million. Vascular Biogenics had a negative return on equity of 35.35% and a negative net margin of 3,021.20%.

VBLT has been the subject of a number of recent research reports. Oppenheimer initiated coverage on Vascular Biogenics in a research report on Thursday, June 27th. They issued an “outperform” rating and a $2.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research report on Thursday, May 16th. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, CIBC initiated coverage on Vascular Biogenics in a research report on Thursday, June 27th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $2.38.

A number of large investors have recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC bought a new stake in Vascular Biogenics in the first quarter valued at approximately $25,000. Menta Capital LLC bought a new stake in Vascular Biogenics in the first quarter valued at approximately $35,000. Ladenburg Thalmann Financial Services Inc. lifted its position in Vascular Biogenics by 66.7% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 15,000 shares during the last quarter. First Republic Investment Management Inc. lifted its position in Vascular Biogenics by 7.4% in the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Morgan Stanley lifted its position in Vascular Biogenics by 6.5% in the second quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 17,900 shares during the last quarter. Institutional investors own 5.93% of the company’s stock.

NASDAQ:VBLT traded up $0.03 during mid-day trading on Thursday, reaching $1.17. The stock had a trading volume of 4,968 shares, compared to its average volume of 102,207. The firm has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $1.36. The stock has a market capitalization of $41.62 million, a P/E ratio of -1.89 and a beta of -0.33. Vascular Biogenics has a one year low of $0.60 and a one year high of $1.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.45 and a current ratio of 6.45.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Recommended Story: Municipal Bonds

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.